Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial

BACKGROUND: Reduction of low-density lipoprotein cholesterol (LDL-C) is important for patients with a high risk for atherosclerotic events, such as patients with diabetes and other risk factors. Anagliptin was reported to reduce LDL-C for 12 weeks in phase III trials regardless of the use of statins...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, Shinichiro, Shimabukuro, Michio, Arasaki, Osamu, Node, Koichi, Nomiyama, Takashi, Morimoto, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843683/
https://www.ncbi.nlm.nih.gov/pubmed/29435776
http://dx.doi.org/10.1007/s10557-018-6776-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843683/
https://www.ncbi.nlm.nih.gov/pubmed/29435776
http://dx.doi.org/10.1007/s10557-018-6776-z

Ejemplares similares